Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead 
Welcome,         Profile    Billing    Logout  
 50 Diseases   11 Trials   11 Trials   833 News 
19 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
2013-001225-11: Comparison of two medicines in heartr perfusion stress studies. Adenosiinin ja regadenosonin vertailu sydänlihaksen verenvirtauksen PET tutkimuksessa sepelvaltimotautia sairastavilla potilailla

Ongoing
4
30
Europe
Adenocor, Rapidcan, Injection, Adenocor, Rapiscan
Turku University Hospital, Turku University Hospital, RapidScan Pharma/Cardirad Finland
Coronary artery desease Sepelvaltimotauti, Coronary artery desease Sepelvaltimotauti, Diseases [C] - Cardiovascular Diseases [C14]
 
 
2022-001452-42: EVALUATION OF PATIENTS WITH TOTAL CORONARY OCCLUSIONS WITH MULTIMODALITY IMAGE EVALUACIÓN DE PACIENTES CON OCLUSIONES CRÓNICAS TOTALES CORONARIAS CON IMAGEN MULTIMODAL.

Not yet recruiting
4
78
Europe
Solution for injection, Rapiscan, Eufilina, Clariscan
HOSPITAL CLINIC BARCELONA, HOSPITAL CLINIC BARCELONA
Coronary artery chronic total occlusion Oclusión crónica total coronaria, Chronic total occlusion of an artery of the heart Obstrucción total de larga duración en arterias del corazón, Diseases [C] - Cardiovascular Diseases [C14]
 
 
NCT03102125: Allograft Dysfunction in Heart Transplant

Recruiting
4
376
US
Regadenoson, Lexiscan
Paul Kim
Heart Transplant Failure and Rejection
12/25
12/25
NCT02130453: Accuracy of an Echo-Stress Protocol Using Regadenoson With Speckle Tracking

Completed
4
161
US
Regadenoson
M.D. Anderson Cancer Center, Astellas Scientific & Medical Affairs, Inc.
Ischemia
06/24
06/24
ChiCTR2400086198: Regadenoson Improve Microvascular dysfunction and Clinical Prognosis in STEMI patients undergoing primary percutaneous coronary intervention: a Randomised Controlled Trial (REVERSE)

Recruiting
4
380
 
Reganosen was given 0.4mg intravenous infusion, and 10 minutes later, Reganosen was given 15ug/min maintenance treatment for 1 hour.; 0.4mg of normal saline was injected intravenously, and 15ug/min of normal saline was given for 1 hour after 10 minutes.; Reganosen was given 0.4mg intravenous infusion, and 10 minutes later, Reganosen was given 15ug/min maintenance treatment for 1 hour.
Zhongshan Hospital Affiliated to Fudan University; Zhongshan Hospital Affiliated to Fudan University, Fudan University Affiliated Zhongshan Hospital 2023 Special fund for clinical research
Coronary heart disease
 
 
2018-003284-62: Rescue with Regadenoson (ReWiRe)

Not yet recruiting
2
98
Europe
Rapiscan, Injection, Rapiscan
Queen Mary University London, Bart's Charity, J P Moulton Charitable Foundation
Cardiovascular collapse following traumatic haemorrhage, Heart failure caused by major bleeding after injury, Diseases [C] - Injuries, poisonings, and occupational diseases [C21]
 
 
NCT05583721: Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET

Recruiting
2
40
US
[13N]NH3, [N-13] Ammonia, azane, CAS# 34819-78-8, Lexiscan, Regadenoson, Positron emission tomography, PET
St. Jude Children's Research Hospital
Sickle Cell Disease
09/25
09/26
2019-002615-25: A clinical trial to be conducted in many hospitals and in different countrieswith the medicinal substance Regadenoson to be used in a type of heart scan called ‘radionuclide myocardial perfusion imaging’ to see the blood flow in the heart muscle in patients aged between 1 month - 18 years.

Not yet recruiting
1/2
54
Europe
Regadenoson, [-], Solution for injection, Rapiscan
GE Healthcare Ltd., GE HEALTHCARE, GE Healthcare Ltd.
Patients who need to undergo a clinically indicated pharmacologic stress perfusion CMR test and who are considered fit for a pharmacological stress perfusion CMR by the investigator. The pharmacologic stress perfusion CMR may be performed in patients for further evaluation of cardiovascular conditions or diseases, such as, but not limited to, Kawasaki disease, congenital heart diseases, congenital coronary abnormalities, and post-cardiac surgery / transplantation, etc., Rapiscan is used in a type of heart scan called myocardial perfusion imaging. It belongs to a group of medicines called coronary vasodilators. It makes heart arteries expand and heart rate increase., Diseases [C] - Cardiovascular Diseases [C14]
 
 
NCT04606069: Treat COVID-19 Patients With Regadenoson

Completed
1/2
5
US
Regadenoson, LEXISCAN,, Placebo Control, Saline
University of Maryland, Baltimore
COVID-19, Lung Inflammation
04/23
04/23
Rapiscan PIP, NCT04604782 / 2019-002615-25: A Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients

Recruiting
1/2
54
Europe
Regadenoson, Rapiscan
GE Healthcare, Covance
Myocardial Ischemia, Coronary Artery Disease
12/26
12/26
NCT04600115: New MRI Methods Applied to Heart Failure With Preserved Ejection Fraction (HFpEF)

Recruiting
1
100
US
Adenosine, Adenoscan, Adenocard, Regadenoson, Lexiscan, O-15 labeled radioactive water, O-15 water, MRI, PET Imaging, Positron Emission Tomography Imaging
University of Utah, National Heart, Lung, and Blood Institute (NHLBI)
MRI Scans
03/22
03/23
NCT03971734: Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas

Terminated
1
7
US
Regadenoson 0.05mg, Regadensoson 0.1mg, Regadensoson 0.2mg, Regadensoson 0.4mg, Regadensoson 0.7mg, Regadensoson 1.0mg, Regadensoson 1.4mg
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Cancer Institute (NCI)
High Grade Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Glioblastoma
04/22
10/23
NCT04521569: Regadenoson Infusion of Marginalized Donor Lungs in an EVLP System

Completed
1
47
US
Regadenoson, Lexiscan, Placebo, Steen solution
University of Maryland, Baltimore, National Heart, Lung, and Blood Institute (NHLBI)
Lung Transplant
06/24
07/24
RJNS-NJHM01, ChiCTR1800014649: Evaluation of the Accuracy and Safety of Regadenoson Injection as A Stress Drug of Myocardial Perfusion Imaging (MPI), A Multicenter, Random, Open, Adenosine Positive Control trial

Recruiting
N/A
 
Fudan University Affiliated Zhongshan Hospital; Nanjing Healmed Biological Medicine Company, Nanjing Healmed Biological Medicine Company
coronary artery disease
 
 
NCT01566890: Microvascular Blood Flow in Sickle Cell Anemia

Completed
N/A
91
US
regadenoson infusion with contrast-enhanced ultrasound, Lexiscan, regadenoson, contrast-enhanced ultrasound
Versiti, Medical College of Wisconsin, La Jolla Institute for Allergy & Immunology, University of Illinois at Chicago, Oregon Health and Science University, Dana-Farber Cancer Institute
Sickle Cell Disease, Sickle Cell Anemia
07/19
11/20
NCT01719016: Improvement Assessment of Coronary Flow Dysfunction Using Fundamental Fluid Dynamics

Active, not recruiting
N/A
68
US
Cardiac PET, Coronary catheterization, Volcano therapeutics, Combomap machine, Adenosine, Lexiscan, N-13 Ammonia
University of Cincinnati
Coronary Artery Disease
06/24
06/24
NCT04316676: The MATCH Investigation: CT Myocardial Perfusion and CT-FFR vs PET MPI

Recruiting
N/A
20
US
PET-MPI Protocol, CT-MPI, CT-FFR, Regadenoson, Lexiscan
Emory University, Siemens Medical Solutions
Coronary Artery Disease
12/24
12/24
NCT06246188: Use of Stress-CMR Using Regadenoson and GE-267 in Adult Patients With Known or Suspected Coronary Artery Disease

Not yet recruiting
N/A
80
Europe
Cardiac MRI using Regadenoson and GE-267
German Heart Institute, GE Healthcare
Coronary Artery Disease
11/24
07/25
NCT03064295: Whole-Heart Myocardial Blood Flow Quantification Using MRI

Recruiting
N/A
160
US
Myocardial Perfusion Cardiac MRI., Myocardial Perfusion imaging, Myocardial Perfusion CMR, Magnetic Resonance Imaging, First Pass Myocardial Perfusion Imaging, Contrast, contrast media, Gadavist, MultiHance, Pharmacologic Stress Agent, regadenoson, adenosine, stress agent
Cedars-Sinai Medical Center, National Heart, Lung, and Blood Institute (NHLBI)
Coronary Artery Disease, Coronary Microvascular Disease
01/25
01/25

Download Options